Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
All News
Infection in the setting of autoimmune rheumatic disease (ARD) has been the subject of increasing research and clinical interest for decades. Despite the huge burden of infection in patients with ARDs, this area of research has really been catapulted to the centre-stage of research agendas and coverage at congresses, including ACR 2020, with the arrival of the coronavirus disease 2019 (COVID-19) pandemic.
Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.
In this compilation from the past week we talk about
- HIV and arthritis
- Hyperuricemia in PsA
- An odd kind of dermatomyositis
The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.
